• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Can-Fite Biopharma Ltd ADR (NY: CANF )

    2.190 +0.040 (+1.86%)
    Official Closing Price Updated: 6:30 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Can-Fite Biopharma Ltd ADR

    < Previous 1 2 3 4 5 6 7 Next >
    Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?
    Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of  
    Via Benzinga
    Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Recap: Can Fite Biofarma Q1 Earnings
    Via Benzinga
    Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
    Via Benzinga
    Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
    Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers 
    Via MarketBeat
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.